<GlossaryTerm id="CDR0000537263"><TermName>lexatumumab</TermName><TermPronunciation>(lek-suh-TOO-moo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. Lexatumumab is a type of monoclonal antibody. Also called anti-TRAIL R2 mAb HGS-ETR2 and HGS-ETR2.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718243" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lexatumumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718242" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lexatumumab&quot;" language="es" id="_4"/><SpanishTermName>lexatumumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. Se une con una proteína que se llama TRAIL-R2 de la superficie de algunas células tumorales, lo que podría destruir estas células. El lexatumumab es un tipo de anticuerpo monoclonal. También se llama HGS-ETR2 y mAb HGS-ETR2 anti-TRAIL R2.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-07-06</DateFirstPublished><DateLastModified>2009-05-08</DateLastModified></GlossaryTerm>
